Angelos Koutras Selected Research

Phenobarbital (Luminal)

1/2017	Protein expression patterns of cell cycle regulators in operable breast cancer.
5/2016	TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
1/2016	Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study.
1/2015	Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.
6/2014	The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping.
1/2014	Differential expression of the insulin-like growth factor receptor among early breast cancer subtypes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Angelos Koutras Research Topics

Disease

57	Neoplasms (Cancer) 12/2023 - 07/2002
54	Breast Neoplasms (Breast Cancer) 12/2023 - 03/2006
8	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2023 - 01/2007
6	Peripheral Nervous System Diseases (PNS Diseases) 01/2007 - 08/2005
4	Lung Neoplasms (Lung Cancer) 01/2023 - 11/2009
3	Renal Cell Carcinoma (Grawitz Tumor) 05/2021 - 04/2019
3	Carcinoma (Carcinomatosis) 05/2019 - 06/2014
3	Adenocarcinoma 05/2019 - 01/2007
3	Neoplasm Metastasis (Metastasis) 05/2019 - 12/2016
3	Colorectal Neoplasms (Colorectal Cancer) 04/2018 - 01/2011
2	Colonic Neoplasms (Colon Cancer) 04/2020 - 01/2007
2	Disease Progression 01/2018 - 07/2004
2	Thrombosis (Thrombus) 02/2016 - 06/2010
2	Anemia 02/2016 - 06/2003
1	Circulating Neoplastic Cells 12/2022
1	Residual Neoplasm 10/2022
1	Sarcoma (Soft Tissue Sarcoma) 10/2022
1	Kidney Neoplasms (Kidney Cancer) 05/2021
1	Head and Neck Neoplasms (Head and Neck Cancer) 03/2021
1	Adenoma (Adenomas) 04/2018
1	Adenocarcinoma of Lung 12/2016

Drug/Important Bio-Agent (IBA)

20	Proteins (Proteins, Gene)FDA Link 12/2022 - 01/2012
16	Messenger RNA (mRNA)IBA 03/2023 - 01/2012
15	Trastuzumab (Herceptin)FDA Link 10/2022 - 03/2013
15	ParaffinIBA 01/2020 - 01/2012
13	Biomarkers (Surrogate Marker)IBA 10/2022 - 09/2011
12	Formaldehyde (Formol)FDA Link 01/2020 - 01/2012
11	AnthracyclinesIBA 01/2022 - 01/2012
11	Paclitaxel (Taxol)FDA LinkGeneric 01/2020 - 08/2005
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/2021 - 01/2011
6	Docetaxel (Taxotere)FDA Link 12/2023 - 01/2007
6	ErbB Receptors (EGF Receptor)IBA 10/2022 - 05/2011
6	human ERBB2 proteinIBA 10/2022 - 01/2019
6	Phenobarbital (Luminal)FDA Link 01/2017 - 01/2014
6	Hormones (Hormone)IBA 01/2016 - 01/2012
5	taxaneIBA 01/2020 - 01/2007
5	Cisplatin (Platino)FDA LinkGeneric 01/2007 - 08/2005
4	Epirubicin (Ellence)FDA LinkGeneric 12/2023 - 01/2012
4	Taxoids (Taxanes)IBA 01/2022 - 07/2014
4	Bevacizumab (Avastin)FDA Link 04/2019 - 09/2011
3	PTEN Phosphohydrolase (PTEN Phosphatase)IBA 05/2019 - 01/2015
3	Cyclin D1IBA 01/2019 - 01/2017
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2023 - 01/2020
2	RNA (Ribonucleic Acid)IBA 01/2023 - 05/2015
2	Tamoxifen FDA LinkGeneric 01/2022 - 08/2019
2	LigandsIBA 01/2022 - 01/2018
2	thiamine triphosphorate (TTP)IBA 01/2022 - 01/2018
2	NivolumabIBA 01/2022 - 01/2020
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2021 - 12/2016
2	Protein Isoforms (Isoforms)IBA 04/2021 - 10/2014
2	Immune Checkpoint InhibitorsIBA 06/2020 - 05/2020
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 04/2020 - 01/2007
2	Fluorouracil (Carac)FDA LinkGeneric 04/2020 - 01/2020
2	Methotrexate (Mexate)FDA LinkGeneric 01/2020 - 02/2011
2	Estrogen ReceptorsIBA 08/2019 - 01/2012
2	TOR Serine-Threonine KinasesIBA 04/2019 - 01/2016
2	CyclinsIBA 01/2019 - 01/2017
2	Somatomedin Receptors (Somatomedin Receptor)IBA 11/2018 - 01/2014
2	Vascular Endothelial Growth Factor CIBA 01/2018 - 09/2015
2	OsteopontinIBA 01/2017 - 09/2015
2	DNA (Deoxyribonucleic Acid)IBA 05/2016 - 01/2013
2	Androgen Receptors (Androgen Receptor)IBA 01/2015 - 06/2014
2	Phosphotransferases (Kinase)IBA 01/2015 - 05/2011
2	ixabepilone (BMS 247550)FDA Link 10/2014 - 01/2013
2	Carboplatin (JM8)FDA LinkGeneric 01/2007 - 12/2005
2	PlatinumIBA 01/2007 - 01/2006
2	Vitamin E FDA LinkGeneric 11/2006 - 09/2006
1	antineoplaston A10 (A 10)IBA 11/2022
1	TNF Receptor-Associated Factor 3IBA 11/2022
1	Circulating Tumor DNAIBA 10/2022
1	Anaplastic Lymphoma KinaseIBA 10/2022
1	pertuzumabIBA 01/2022
1	LipofuscinIBA 01/2022
1	VinculinIBA 01/2022
1	pembrolizumabIBA 01/2022
1	Coloring Agents (Dyes)IBA 01/2022
1	Tyrosine Kinase InhibitorsIBA 10/2021
1	Gefitinib (Iressa)FDA Link 10/2021
1	CD40 AntigensIBA 01/2021
1	B-Cell Activation Factor ReceptorIBA 01/2021
1	Lymphotoxin beta ReceptorIBA 01/2021
1	Transcription Factors (Transcription Factor)IBA 01/2021
1	CytokinesIBA 01/2020
1	ChemokinesIBA 01/2020
1	cabazitaxel FDA Link 01/2020
1	Actins (F Actin)IBA 08/2019
1	temsirolimus FDA Link 04/2019
1	Monoclonal AntibodiesIBA 11/2018
1	Insulin-Like Growth Factor I (IGF-1)IBA 11/2018
1	Cell-Free Nucleic AcidsIBA 04/2018

Therapy/Procedure

30	Drug Therapy (Chemotherapy) 12/2023 - 07/2002
18	Adjuvant Chemotherapy 11/2022 - 01/2012
6	Therapeutics 10/2022 - 01/2007
2	Precision Medicine 10/2022 - 01/2020
2	Aftercare (After-Treatment) 10/2022 - 08/2019
2	Immunotherapy 01/2022 - 05/2020
2	Semiconductors 05/2016 - 01/2016
1	Molecular Targeted Therapy 10/2022
1	Radiotherapy 05/2021
1	Particle Accelerators 05/2021